This high specificity and redundancy in functioning modalities has made Cetuximab the ideal compound for targeted therapy in tumors driven by EGFR upregulation, such as human head and neck SCC (HNSCC) (3). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.